SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRANCHINI, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.830
EU - Europa 7.493
AS - Asia 6.028
SA - Sud America 847
AF - Africa 172
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 10
Totale 24.391
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.562
FI - Finlandia 3.931
SG - Singapore 2.296
CN - Cina 1.438
IT - Italia 1.424
VN - Vietnam 729
BR - Brasile 645
DE - Germania 515
HK - Hong Kong 465
PL - Polonia 313
GB - Regno Unito 289
UA - Ucraina 239
TR - Turchia 210
FR - Francia 202
JP - Giappone 192
IN - India 159
ID - Indonesia 139
CA - Canada 135
RU - Federazione Russa 132
MX - Messico 107
SE - Svezia 106
NL - Olanda 75
BD - Bangladesh 74
AR - Argentina 71
ZA - Sudafrica 69
IQ - Iraq 51
ES - Italia 40
PK - Pakistan 39
EC - Ecuador 34
BE - Belgio 33
CZ - Repubblica Ceca 29
MY - Malesia 26
CL - Cile 24
CO - Colombia 24
MA - Marocco 24
NO - Norvegia 24
VE - Venezuela 24
SA - Arabia Saudita 21
AT - Austria 20
LT - Lituania 20
DK - Danimarca 18
RO - Romania 18
IR - Iran 17
PH - Filippine 17
UZ - Uzbekistan 17
IE - Irlanda 16
TW - Taiwan 16
AE - Emirati Arabi Uniti 15
KE - Kenya 15
JO - Giordania 14
DZ - Algeria 13
ET - Etiopia 12
KR - Corea 11
NP - Nepal 11
EG - Egitto 10
EU - Europa 10
AU - Australia 9
AZ - Azerbaigian 9
IL - Israele 9
NG - Nigeria 7
PT - Portogallo 7
PY - Paraguay 7
TH - Thailandia 7
UY - Uruguay 7
AL - Albania 6
CH - Svizzera 6
GE - Georgia 6
PE - Perù 6
TN - Tunisia 6
CR - Costa Rica 5
GR - Grecia 5
KZ - Kazakistan 5
LB - Libano 5
BH - Bahrain 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
HR - Croazia 4
JM - Giamaica 4
KG - Kirghizistan 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BG - Bulgaria 3
KW - Kuwait 3
PS - Palestinian Territory 3
AF - Afghanistan, Repubblica islamica di 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
EE - Estonia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
RE - Reunion 2
RS - Serbia 2
SI - Slovenia 2
Totale 24.365
Salva come PNG Salva come JPEG
Città #
Helsinki 3.838
Singapore 1.410
Ashburn 1.044
Dallas 1.021
San Jose 742
Chandler 570
Fairfield 504
Santa Clara 495
Beijing 449
Woodbridge 441
Hong Kong 436
Ferrara 352
Warsaw 305
Houston 290
Ann Arbor 277
New York 257
Ho Chi Minh City 248
Seattle 221
Wilmington 221
Jacksonville 217
Los Angeles 208
Tokyo 181
Council Bluffs 176
Cambridge 173
Hanoi 165
Munich 161
Izmir 121
Princeton 119
Milan 117
Jakarta 106
Lauterbourg 104
Nanjing 101
Shanghai 97
Dearborn 88
São Paulo 79
Boardman 66
Bremen 62
Rome 62
The Dalles 62
Mexico City 61
Orem 59
London 57
Montreal 46
San Diego 46
Toronto 46
Denver 45
Turku 43
Redwood City 41
Atlanta 40
Brooklyn 39
Frankfurt am Main 39
Johannesburg 39
Chennai 38
Bologna 36
Nanchang 36
Falls Church 35
Shenyang 34
Poplar 33
Florence 31
Tianjin 31
Guangzhou 30
Chicago 29
Da Nang 29
Haiphong 29
Manchester 29
Phoenix 28
Buffalo 26
Falkenstein 26
Moscow 26
Brussels 25
Hefei 25
Amsterdam 23
Baghdad 23
Dong Ket 23
Hebei 21
Jiaxing 21
Nuremberg 21
Rio de Janeiro 21
San Francisco 21
Auburn Hills 20
San Mateo 20
Changsha 19
Mumbai 19
Ankara 18
Jinan 18
Paris 18
Stockholm 18
Biên Hòa 17
Boston 17
Brno 17
Oslo 17
Columbus 16
Hangzhou 16
Kunming 16
Tashkent 16
Hải Dương 15
Norwalk 15
Querétaro 15
Belo Horizonte 14
Zhengzhou 14
Totale 17.292
Salva come PNG Salva come JPEG
Nome #
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 2.855
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 2.043
La sanificazione delle degenze ospedaliere: nuove strategie per la riduzione delle infezioni correlate all’assistenza sanitaria 448
La sanificazione delle degenze ospedaliere: nuove strategie a supporto della riduzione delle infezioni correlate all’assistenza sanitaria 399
Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation 346
Il sistema di sanificazione PCHS Probiotic Cleaning Hygien System: risultati delle indagini sperimentali in vitro e in campo 325
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 300
The carboxyl-terminal region of coagulation factors: role in biosynthesis and function of FVII and FX 299
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 297
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 285
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 283
Hard surface biocontrol in hospitals using microbial-based cleaning products 264
PCHS (Probiotic Hygiene Cleaning System) Protocol: reduction of hospital environmental impact with a new and innovative technology for cleaning in Ferrara University Hospital 263
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 241
Reduction of the microbial load on hospital surfaces through probiotic-based cleaning procedures: a new strategy to control nosocomial infections 239
Chronic sleep deprivation markedly reduces coagulation factor VII expression 237
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 234
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 232
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 228
I probiotici: aspetti generali e valutazioni sulla sicurezza d’impiego 221
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 219
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 212
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 210
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 204
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 203
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 203
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 202
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 198
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 195
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 186
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 186
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 184
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 183
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 183
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 180
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 180
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 179
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 178
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 177
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 176
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 175
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 175
Improved intracellular processing of protein variants as a personalized therapeutic approach for Haemophilia 166
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 164
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 162
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 162
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 162
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 162
Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants 161
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 161
F9 genotype and PK hemophilia B international study (GEPKHIS) 160
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 158
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 158
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 156
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 155
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 153
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 152
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 152
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 151
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 151
An engineered factor X variant as a novel by-passing agent for hemophilia 150
Hemostasis gene expression of the internal jugular and saphenous veins 150
Comparative Analysis Of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B- domain Favours Readthrough- mediated Protein Output 145
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 144
Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies 143
A recoded view on the F9 p.Cys178Ter pathogenic mechanism 141
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 140
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 139
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 139
An integrated multi-tool analysis contributes elements to interpreting unclassified factor IX missense variants associated with haemophilia B 136
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 136
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 135
Academic Editor per la rivista PLoS One 134
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 133
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 131
The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity 129
A new type 1 von Willebrand Disease (VWD) characterized by increased clearance of von Willebrand Factor (VWF) due to the heterozygous p.P1127S mutation: clinical phenotype and pathogenic mechanisms 128
Effects of Partial Chronic Sleep Deprivation on the Mouse Blood Coagulation Cascade. 127
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 126
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 126
Translation termination codons in protein synthesis and disease 125
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity 124
A factor X variant with engineered activation peptide as innovative by-passing agent for haemophilia 124
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 122
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 119
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 117
Next generation factor VIIa with enhanced half-life 115
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 111
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 110
Naturally occurring truncated proteins: decreased protein secretion and increased activity result in asymptomatic coagulation factor deficiency 106
“Compensatory” aberrant splicing supports residual expression levels in severe coagulation factor VII deficiency 105
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 103
Engineered suppressor tRNAs as a novel correction approach for recurrent hemophilia A-causing nonsense mutations 100
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 99
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 99
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 98
Associate Editor per la rivista Frontiers in Pediatrics - sezione Genetic Disorders 97
null 94
The carboxyl-terminal region of coagulation serine proteases: A matter of cut and change 94
null 93
Totale 21.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 629
Totale 94.243
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021264 0 0 0 0 0 0 0 0 0 0 179 85
2021/20221.181 170 139 37 36 82 72 49 48 35 84 74 355
2022/20231.242 132 144 50 174 179 158 77 79 135 11 58 45
2023/2024856 63 67 44 32 54 156 41 62 29 33 44 231
2024/20253.349 102 78 302 108 394 371 78 90 523 383 507 413
2025/202613.295 944 550 1.259 1.308 1.385 652 1.158 474 4.600 963 2 0
Totale 24.783